211 related articles for article (PubMed ID: 32835553)
1. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
Patel KK; Isufi I; Kothari S; Foss F; Huntington S
Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
[TBL] [Abstract][Full Text] [Related]
2. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Flowers CR; Matasar MJ; Herrera AF; Hertzberg M; Assouline S; Demeter J; McMillan A; Mehta A; Opat S; Trnňný M; Musick L; Hirata J; Yang A; Sehn LH
Haematologica; 2024 Apr; 109(4):1194-1205. PubMed ID: 37767550
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
Liao MZ; Lu D; Lu T; Gibiansky L; Deng R; Samineni D; Dere R; Lin A; Hirata J; Shen BQ; Zhang D; Li D; Li C; Miles D
Adv Drug Deliv Rev; 2024 Apr; 207():115193. PubMed ID: 38311111
[TBL] [Abstract][Full Text] [Related]
4. [Successful polatuzumab vedotin and rituximab therapy for post-CAR-T relapse of diffuse large B-cell lymphoma].
Kushida T; Hirosawa M; Goto M; Seike Y; Kitamura N; Nakanishi T; Tanaka A; Higashi T; Morimoto H; Tsukada J
Rinsho Ketsueki; 2024; 65(3):180-182. PubMed ID: 38569863
[TBL] [Abstract][Full Text] [Related]
5. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Shi R; Lu T; Ku G; Ding H; Saito T; Gibiansky L; Agarwal P; Li X; Jin JY; Girish S; Miles D; Li C; Lu D
Cancer Chemother Pharmacol; 2020 Sep; 86(3):347-359. PubMed ID: 32770353
[TBL] [Abstract][Full Text] [Related]
6. Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
Shaw B; Chung E; Wellard C; Yoo E; Bennett R; Birks C; Johnston A; Cheah CY; Hamad N; Simpson J; Barraclough A; Ku M; Viiala N; Ratnasingam S; Armytage T; Cochrane T; Chong G; Lee D; Manos K; Keane C; Wallwork S; Opat S; Hawkes EA
EJHaem; 2024 Apr; 5(2):325-332. PubMed ID: 38633125
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland.
Moradi-Lakeh M; Yaghoubi M; Seitz P; Javanbakht M; Brock E
Adv Ther; 2021 Jun; 38(6):3427-3443. PubMed ID: 34021886
[TBL] [Abstract][Full Text] [Related]
8. Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma.
Assi R; Masri N; Dalle IA; El-Cheikh J; Ghanem H; Bazarbachi A
Clin Hematol Int; 2021 Mar; 3(1):21-26. PubMed ID: 34595463
[TBL] [Abstract][Full Text] [Related]
9. Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis.
Russler-Germain DA; Cliff ERS; Bartlett NL
Blood; 2023 Dec; 142(25):2216-2219. PubMed ID: 37797275
[TBL] [Abstract][Full Text] [Related]
10. Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma.
Corcoran SR; Phelan JD; Choi J; Shevchenko G; Fenner RE; Yu X; Scheich S; Hsiao T; Morris VM; Papachristou EK; Kishore K; D'Santos CS; Ji Y; Pittaluga S; Wright GW; Urlaub H; Pan KT; Oellerich T; Muppidi J; Hodson DJ; Staudt LM
Cancer Discov; 2024 Apr; ():. PubMed ID: 38683128
[TBL] [Abstract][Full Text] [Related]
11. Rituximab or cyclosporine a for the treatment of membranous nephropathy: Economic evaluation of the MENTOR trial.
Kadatz M; Klarenbach S; So H; Fervenza FC; Cattran DC; Barbour SJ
Nephrol Dial Transplant; 2024 Apr; ():. PubMed ID: 38621719
[TBL] [Abstract][Full Text] [Related]
12. Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX.
Liao MZ; Deng R; Gibiansky L; Lu T; Agarwal P; Dere R; Lee C; Hirata J; Herbaux C; Salles G; Li C; Miles D
Clin Transl Sci; 2023 Dec; 16(12):2744-2755. PubMed ID: 37864313
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
Deng R; Gibiansky L; Lu T; Flowers CR; Sehn LH; Liu Q; Agarwal P; Liao MZ; Dere R; Lee C; Man G; Hirata J; Li C; Miles D
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; ():. PubMed ID: 38622879
[TBL] [Abstract][Full Text] [Related]
14. Disseminated tuberculosis after Polatuzumab-Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma.
Elkourashy SA; Benkhadra M; Shafei L; Abujarir S; Ghasoub R
Clin Case Rep; 2024 May; 12(5):e8838. PubMed ID: 38721565
[TBL] [Abstract][Full Text] [Related]
15. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
Betts KA; Thuresson PO; Felizzi F; Du EX; Dieye I; Li J; Schulz M; Masaquel AS
J Comp Eff Res; 2020 Oct; 9(14):1003-1015. PubMed ID: 33028076
[No Abstract] [Full Text] [Related]
16. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
Burke JM; Morschhauser F; Andorsky D; Lee C; Sharman JP
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1073-1083. PubMed ID: 32985934
[TBL] [Abstract][Full Text] [Related]
17. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
18. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
Segman Y; Ribakovsky E; Avigdor A; Goldhecht Y; Vainstein V; Goldschmidt N; Harlev S; Horwitz N; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Zektser M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Herishanu Y; Ram R; Perry C; Avivi I
Leuk Lymphoma; 2021 Jan; 62(1):118-124. PubMed ID: 32981410
[TBL] [Abstract][Full Text] [Related]
19. Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Camus V; Tilly H
Future Oncol; 2021 Jan; 17(2):127-135. PubMed ID: 32954807
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma.
Thuresson PO; Vander Velde N; Gupta P; Talbot J
Adv Ther; 2020 Dec; 37(12):4877-4893. PubMed ID: 33001384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]